Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) Net Income towards Common Stockholders (2024 - 2025)

Historic Net Income towards Common Stockholders for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to -$20.4 million.

  • Prelude Therapeutics' Net Income towards Common Stockholders rose 4060.39% to -$20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$54.2 million, marking a year-over-year change of. This contributed to the annual value of -$139.7 million for FY2024, which is N/A changed from last year.
  • Prelude Therapeutics' Net Income towards Common Stockholders amounted to -$20.4 million in Q3 2025, which was up 4060.39% from -$33.8 million recorded in Q4 2024.
  • In the past 5 years, Prelude Therapeutics' Net Income towards Common Stockholders ranged from a high of -$20.4 million in Q3 2025 and a low of -$34.4 million during Q3 2024